This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): acyclovir
Description: The viral enzyme thymidine kinase encoded by HSV and VZV converts Zovirax into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In vitro, acyclovir triphosphate stops replication of herpes viral DNA. This is accomplished in 3 ways:
- 1) competitive inhibition of viral DNA polymerase,
- 2) incorporation into andtermination of the growing viral DNA chain, and
- 3) inactivation of the viral DNA polymerase.
The greater antiviral activity of zovirax against HSV compared to VZV is due to its moreefficient phosphorylation by the viral thymidine kinase.
Deal Structure: Zovirax was originally developed by GSK.
GSK and Biovail
In October 2001, Biovail acquired exclusive promotion and distribution rights for Zovirax Ointment for the United States and Puerto Rico. Under the terms of the agreement, GSK will manufacture and supply Zovirax Ointment and Zovirax Cream to Biovail and, in return, Biovail will pay GSK $133 million for certain rights to the product, subject to certain conditions.
Valeant and Biovail
In June 2010, Valeant and Biovail announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International. This acquisition closed in September 2010.
Valeant and GSK
In February 2011, Valeant announced that its subsidiary, Biovail, signed agreements to acquire all U.S. and Canadian rights to non-opthalmic topical...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc
Pink Sheet GSK Discontinues Zovirax Dose
Pink Sheet Burroughs Wellcome/Wyeth-Ayerst
Additional information available to subscribers only: